医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Lianhua Qingwen Capsule Obtained Approval in the Philippines, and the Chinese Embassy in the Philippines Issued Statement for Congratulation

2020年12月03日 PM12:00
このエントリーをはてなブックマークに追加


 

SHIJIAZHUANG CITY, China

Lianhua Qingwen Capsule, a Chinese traditional medicine made by Yiling Pharmaceutical, has played an important role in China’s COVID-19 prevention and control. The herb medicine has the effects of clearing away the plague, detoxifying, releasing lung heat. Lianhua Qingwen has been approved by the Food and Drug Administration of the Philippines and become officially registered in the Philippines. It entered the Philippine market on November 23.

In August 2020, spokesperson from the Embassy of the People’s Republic of China in the Philippines has specially issued The Statement on Lianhua Qingwen Capsule Obtaining Philippine Drug Registration Certificate, to congratulate the approval.

The statement pointed out that the embassy was very pleased to learn the Food and Drug Administration of the Philippines had officially approved Lianhua Qingwen Capsule produced by Yiling Pharmaceutical, making it a traditional Chinese medicine product officially registered in the Philippines.

The statement shows that Lianhua Qingwen Capsule has obtained listing license in nearly 20 countries, including Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos. It is expected that after entering the Philippine market, Lianhua Qingwen can help effectively curb the spread of the coronavirus and help Philippine patients with mild symptoms quickly recover.

The Chinese Embassy hopes that Philippine consumers purchase and use qualified traditional Chinese medicine products produced by regular manufacturers, and expect Chinese medicine products to play a greater role in fighting COVID-19 in the Philippines.

It is reported that the registration No. of Lianhua Qingwen in the Philippines is THPR-50, with product category as a traditionally-used herbal product. At present, consumers in the Philippines can purchase Lianhua Qingwen at the Southstar Drug, and is going to be on sale at Watsons and Mercury Drug also.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005352/en/

CONTACT

First Name: Li

Last Name: Kristy

E-mail:kristyli@chuhaimedia.com.cn

Phone No.: +86 85962566

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Asia’s Largest Biotech Event, BIO KOREA 2023 to Be Held From May 10 to 12 in Seoul
  • OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration
  • Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
  • 知临集团签署意向书及投资条件书以收购U Group
  • Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)